His interest in immunotherapy is exemplified by his most recent start-up venture, D5Pharma, where he is the co-founder, CSO, and director. Gariépy more recently switched his research focus towards the development of biological therapeutics directed towards combatting cancer and inflammation. Aaron Prodeus, 1, 2 Aws Abdul-Wahid, 2 Nicholas W. (MTI MTEM Austin, Texas), a well-funded, NASDAQ-listed company that focuses on the development of protein-based biotherapeutics (Engineered Toxin Bodies) in the area of Oncology. He co-founded and was a director and CSO of Molecular Templates, Inc. Activity Congratulations to our Chief Scientific Officer, Laura Sepp-Lorenzino, Ph.D. Gariépy has had a long standing interest in developing new technologies in the field of biotherapeutics, being cited as an inventor or co-inventor on multiple granted patents and on more than 20 patent applications. Aaron Prodeus Greater Boston 602 followers 500+ connections Join to view profile Intellia Therapeutics, Inc. He is the Director of the Molecular Targeting and Therapeutics Laboratory at the Sunnybrook Research Institute (SRI), and the SRI Research Chair in Biomolecular Engineering. Jean Gariépy was originally trained as a peptide chemist and biophysicist at the University of Alberta (Ph.D.), and as a peptide/protein engineer at Stanford University, in the areas of bacterial toxins and infectious diseases (as a postdoctoral fellow). Therefore, the results indicate the ability of anti-vascular USMBs to increase the anti-tumor effects of CI therapy the specific mechanisms of enhancement remain to be established.Īnti-PD-1 CT26 Immunotherapy Microbubbles Ultrasound.Ĭopyright © 2018. Aaron Prodeuss 25 research works with 441 citations and 1798 reads, including: Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to. Flow cytometry and ELISPOT data did not clearly support a T cell-dependent mechanism for the enhancement. Longitudinal experiments indicated that USMB + anti-PD-1 treatments significantly enhanced tumor growth inhibition and animal survival relative to monotherapies. The colorectal cancer cell line CT26 was used to conduct longitudinal growth studies along with acute experiments to assess ultrasound-induced anti-tumor immune responses using flow cytometry and enzyme-linked immunospot (ELISPOT) analysis. Aaron is based out of Greater Boston and works in the Biotechnology Research industry. Aaron works at Intellia Therapeutics, Inc. The primary enemies are close matches with Doom‘s rank-and-file demons (Fiends are Imps, Bloaters are Cacodemons, Skull Fish are Lost Souls, etc. View Aaron Prodeus' email address () and phone number. Here we investigate the use of "anti-vascular" ultrasound-stimulated microbubble (USMB) treatments in combination with anti-PD-1 CI therapy. The plot is about as relevant moment-to-moment as Doom‘s.This is a critical comparison, because Prodeus comes off like a particularly thorough total conversion mod for Doom. There are concerted efforts to improve CI therapy through the use of multiple CIs or use of CIs in combination with other anti-cancer agents. Checkpoint inhibitor (CI) immunotherapy is playing an increasingly prominent role in the treatment of cancer but is effective and durable in only a subset of patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |